Ocugen Submits EUA in US for Ages 5-18

 Conference Call and Webcast Today at 8:30 a.m. ET

• Emergency Use Authorization application filed with the U.S. FDA for the COVID-19 vaccine candidate, COVAXIN™ (BBV152), for children aged 2 – 18 years

• Investigational New Drug application filed with the U.S. FDA for COVAXIN™ (BBV152)

• Investigational New Drug application filed with the U.S. FDA for breakthrough modifier gene therapy candidate, OCU400

• Collaboration with CanSinoBIO expanded to include OCU410 for chemistry, manufacturing, and controls development and manufacturing

Conference Call and Webcast Details

Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights. Ocugen's senior management team will host the call, which will be open to all listeners. There will also be a question-and-answer session following the prepared remarks.

The call can be accessed by dialing (844) 873-7330 (U.S.) or (602) 563-8473 (international) and providing the conference ID 8198297. To access a live audio webcast of the call on the “Investors” section of the Ocugen website, please click here. A replay of the webcast will be archived on Ocugen’s website for approximately 45 days following the call.

https://finance.yahoo.com/news/ocugen-provides-business-third-quarter-123000780.html